
The FDA has granted priority review to a non-opioid, postoperative pain treatment, HTX-011…... [Read More]
The FDA has granted priority review to a non-opioid, postoperative pain treatment, HTX-011…... [Read More]
FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising… [Read More]
The FDA has issued new safety guidelines for systemic fluoroquinolones, restricting their use to patients with no alternative treatment options…... [Read More]
• By Saba Ziaee, MD, & Zineb Aouhab, MD
Various drugs are known to cause musculoskeletal symptoms, such as arthralgias, myalgias, drug-induced lupus and serum sickness.1 In the rheumatology world, the most commonly recognized drugs that can cause musculoskeletal symptoms are hydralazine, minocycline, fluoroquinolones and, recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor class of medications. Although beta blockers also have a noted side effect… [Read More]
• By Lara C. Pullen, PhD
Six-week treatment regimen returns same results as 12 weeks in recent study, although researchers caution findings may not apply to all patients with vertebral osteomyelitis... [Read More]
information on new approvals and medication safety... [Read More]
Visit the official website for the American College of Rheumatology.
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.